17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

Neurobiology of Pain & Central Sensitization

Pain is defined by the International Association for the Study of Pain (IASP) as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage." Effective perioperative and critical care analgesia requires an understanding of the physiological pathways of nociception.

The Four Phases of Nociceptive Processing

1. Transduction: Conversion of noxious mechanical, thermal, or chemical stimuli into electrical action potentials by specialized bare peripheral nerve endings (nociceptors). Tissue trauma releases an "inflammatory soup" containing bradykinin, prostaglandins (PGE2), substance P, histamine, serotonin, and protons (H+). These mediators lower the activation threshold of transient receptor potential channels (e.g., TRPV1) and voltage-gated sodium channels (Nav1.7, Nav1.8), producing peripheral sensitization.
2. Transmission: Propagation of action potentials along primary afferent sensory nerve fibers from the periphery to the dorsal horn of the spinal cord:
   • A-delta (A-δ) Fibers: Thinly myelinated, medium diameter (2-5 μm), fast conduction velocity (5 to 30 m/s). Transmit sharp, stinging, highly localized, rapid "first pain" and cool thermal sensation.
   • C Fibers: Unmyelinated, small diameter (0.2-1.5 μm), slow conduction velocity (0.5 to 2 m/s). Transmit dull, burning, aching, throbbing, poorly localized, delayed "second pain".
   • Primary afferents synapse in specific Rexed laminae of the spinal cord dorsal horn: A-delta fibers terminate in Laminae I and V; C fibers terminate predominantly in Lamina II (substantia gelatinosa) and Lamina I.
3. Modulation: Modification of nociceptive transmission within the dorsal horn. Modulatory interneurons release endogenous opioid peptides (endorphins, enkephalins, dynorphins). Descending inhibitory pathways originate in the Periaqueductal Gray (PAG) and the Rostral Ventromedial Medulla (RVM), projecting downward via the dorsolateral funiculus to release norepinephrine (activating alpha-2 receptors) and serotonin (5-HT), which hyperpolarize projection neurons and suppress glutamate and substance P release.
4. Perception: Transmission of ascending signals via the lateral spinothalamic tract to the thalamus, radiating to the primary somatosensory cortex (sensory discrimination of pain location and intensity), the anterior cingulate cortex, and the insular cortex (affective and emotional distress of pain).

Central Sensitization & The "Wind-Up" Phenomenon

Following severe tissue injury or inadequate perioperative analgesia, repetitive, low-frequency C-fiber nociceptive barrages arrive at the spinal dorsal horn:

• Sustained release of excitatory neurotransmitters (glutamate and substance P) causes prolonged depolarization of secondary Wide Dynamic Range (WDR) projection neurons.
• Under resting conditions, the channel pore of the N-methyl-D-aspartate (NMDA) receptor is physically blocked by an extracellular magnesium ion (Mg2+).
• Continuous membrane depolarization drives the magnesium ion out of the channel pore, unmasking the NMDA receptor. Glutamate and glycine binding triggers massive intracellular calcium (Ca2+) influx.
• Intracellular calcium activates protein kinase C (PKC), nitric oxide synthase (NOS), and immediate early genes (c-fos), causing a state of profound neuronal hyperexcitability termed central sensitization (or "wind-up").
• Clinical Manifestations of Central Sensitization:
  • Hyperalgesia: Exaggerated, intense pain perception to a normally mildly noxious stimulus.
  • Allodynia: Perception of pain from normally completely innocuous stimuli (such as light touch of clothing or bedsheets over a surgical wound).
  • Secondary Hyperalgesia: Expansion of receptive pain fields into uninjured surrounding tissue.
  • Transition from acute surgical pain into debilitating chronic post-surgical neuropathic pain.

Rationale for Multimodal Analgesia

Multimodal (balanced) analgesia involves administering combinations of two or more analgesic medications or techniques that act through distinct physiological mechanisms at different anatomical sites along the nociceptive pathway. By attacking nociception simultaneously at peripheral nociceptors, sensory nerve axons, spinal dorsal horn synapses, and descending cortical pathways, multimodal analgesia achieves:

• Synergistic or additive analgesic efficacy.
• A 30% to 50% reduction in total opioid requirements (opioid-sparing effect).
• Significant reductions in opioid-related adverse events: less sedation, lower rates of respiratory depression, decreased postoperative nausea and vomiting (PONV), earlier resolution of postoperative ileus, faster mobilization, and shorter hospital stay.

---

The Analgesic Pharmacopeia: Non-Opioids, Adjuvants & Opioids

1. Non-Opioid Analgesics

• Paracetamol (Acetaminophen):

  • Mechanism of Action: Weak central inhibitor of prostaglandin synthesis (inhibits the peroxidase catalytic site of cyclooxygenase enzymes, COX-1 and COX-2, particularly in areas of low peroxide concentration like the central nervous system; previously termed "COX-3"). Activates descending serotonergic inhibitory pathways and produces an active cannabinoid metabolite (AM404) that stimulates CB1 receptors and TRPV1 channels. Possesses potent analgesic and antipyretic properties, but lacks peripheral anti-inflammatory action.
  • Dosing: Standard adult dose is 1.0 g orally or IV every 6 hours (maximum 4.0 g/day). In patients with chronic alcoholism, hepatic cirrhosis, severe malnutrition, or low body weight (< 50 kg), maximum dose must be reduced to 2.0 to 3.0 g/day.
  • Hepatotoxicity & Antidote: Therapeutic doses are 90% glucuronidated/sulfated; ~5-10% is oxidized by hepatic CYP2E1 into the highly reactive, cytotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). Normally, NAPQI is rapidly detoxified by intracellular hepatic glutathione. In acute overdose (> 150 mg/kg or > 7.5-10 g), glutathione stores are depleted by > 70%; unbound NAPQI covalently binds cysteinyl proteins of hepatocytes, provoking massive centrilobular hepatic necrosis and fulminant liver failure. The specific life-saving antidote is intravenous N-acetylcysteine (NAC), which replenishes intracellular glutathione stores and directly conjugates NAPQI.

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs; Ibuprofen, Ketorolac, Diclofenac):

  • Mechanism of Action: Non-selective competitive inhibition of cyclooxygenase enzymes (COX-1 and COX-2), preventing the conversion of arachidonic acid to pro-inflammatory prostaglandins (PGE2, PGI2) and thromboxane A2. Highly effective for acute somatic, musculoskeletal, bone, and inflammatory visceral pain.
  • Ketorolac Dosing Rule: Ketorolac tromethamine (15-30 mg IV every 6 hours) is a potent parenteral NSAID, but its use is strictly limited to a maximum duration of 5 consecutive days due to high risks of gastrointestinal ulceration and acute renal injury.
  • Clinical Contraindications and Major Precautions for NSAIDs:
    1. Active peptic ulcer disease or acute gastrointestinal hemorrhage (inhibition of COX-1-mediated cytoprotective gastric mucus and bicarbonate secretion).
    2. Acute kidney injury or advanced chronic kidney disease: Avoid NSAIDs; in less severe CKD, any short course requires individual risk assessment and monitoring. Mechanism: Prostaglandins (PGE2, PGI2) maintain tonic vasodilation of the renal afferent arterioles, preserving glomerular filtration rate during hypovolemia or stress. NSAIDs block prostaglandin synthesis, causing unopposed afferent arteriolar vasoconstriction, acute drop in GFR, renal medullary ischemia, and acute tubular/papillary necrosis.
    3. Severe congestive heart failure (causes renal sodium and water retention, blunts diuretic efficacy, worsens pulmonary edema).
    4. Decompensated cirrhosis with ascites (high risk of precipitating hepatorenal syndrome).
    5. Aspirin-Exacerbated Respiratory Disease (AERD / Samter Triad): Asthma, chronic rhinosinusitis with nasal polyps, and severe bronchospasm provoked by COX-1 inhibitors (shunting of arachidonic acid into the 5-lipoxygenase pathway with massive leukotriene release).
    6. Perioperative coronary artery bypass graft (CABG) surgery (increased risk of myocardial infarction and stroke).
    7. Third trimester of pregnancy (causes premature in utero closure of the fetal ductus arteriosus and oligohydramnios).

2. Adjuvant Analgesic Modalities

• Gabapentinoids (Gabapentin, Pregabalin):

  • Mechanism: Structural analogues of GABA that do NOT bind GABA receptors. Instead, they bind with high affinity to the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the spinal cord dorsal horn and brain. This reduces calcium influx into presynaptic nerve terminals, suppressing the exocytosis of excitatory neurotransmitters (glutamate, substance P, calcitonin gene-related peptide [CGRP]).
  • Clinical Indications: Options for initial treatment of neuropathic pain, including diabetic neuropathy and post-herpetic neuralgia. Do not routinely use them for sciatica. Selected perioperative adjunct use requires balancing opioid-sparing benefit against sedation and respiratory risk.
  • Adverse Effects & Renal Elimination: Dizziness, somnolence, ataxia, peripheral edema. Both drugs are eliminated 100% unchanged by the kidneys; dosing must be reduced in patients with chronic kidney disease or elevated serum creatinine. FDA safety warning: Concurrent administration with opioids dramatically increases the risk of severe, fatal respiratory depression.

• Low-Dose Ketamine Infusion:

  • Sub-anesthetic IV ketamine (bolus 0.15-0.25 mg/kg, followed by infusion at 0.1 to 0.3 mg/kg/hr) acts as a potent NMDA receptor antagonist. It uncouples dorsal horn central sensitization, blocks "wind-up", and effectively treats and prevents opioid tolerance and opioid-induced hyperalgesia (OIH).

• Alpha-2 Adrenergic Agonists (Dexmedetomidine):

  • Highly selective alpha-2 adrenoceptor agonist (alpha-2:alpha-1 selectivity ratio 1620:1, eight times more selective than clonidine). Stimulates pre- and post-synaptic alpha-2 receptors in the locus coeruleus of the brainstem.
  • The Clinical Miracle: Produces "cooperative conscious sedation" (patients appear asleep but are easily aroused by verbal or tactile stimuli, cooperative, and oriented) and somatic analgesia WITHOUT producing respiratory depression (minute ventilation and hypercapnic ventilatory drive remain intact).
  • Clinical Role: Extubation bridging, mechanical ventilation weaning in the ICU, awake fibreoptic intubation, and adjuvant opioid-sparing infusions.
  • Hemodynamic Side Effects: Dose-dependent sinus bradycardia and initial transient hypertension (peripheral alpha-2B vasoconstriction) followed by sustained hypotension (central sympatholysis).

• Regional Truncal & Fascial Plane Blocks:

  • Transversus Abdominis Plane (TAP) Block: Local anaesthetic deposited in the neurofascial plane between the internal oblique and transversus abdominis muscles, blocking the anterior rami of lower thoracic spinal nerves (T7-L1). Provides somatic analgesia to the anterior abdominal wall (laparotomy, caesarean section, appendectomy).
  • Erector Spinae Plane (ESP) Block: Local anaesthetic injected deep to the erector spinae muscle superficial to thoracic transverse processes, blocking dorsal and ventral rami of spinal nerves; highly versatile for rib fractures, thoracotomy, and laparoscopic nephrectomy.

3. Opioid Agonists & Patient-Controlled Analgesia (PCA)

Opioid analgesics act as agonists at G-protein-coupled mu opioid receptors distributed throughout the spinal dorsal horn, periaqueductal gray, thalamus, and limbic system. Receptor activation inhibits adenylate cyclase, closes presynaptic voltage-gated calcium channels (inhibiting neurotransmitter release), and opens postsynaptic inward-rectifying potassium channels (hyperpolarizing projection neurons).

Patient-Controlled Analgesia (PCA) Safety Directives

Intravenous PCA allows patients to self-administer small, programmed doses of opioid on demand using an electronic infusion pump:

• Key Parameters:
  • Demand Dose: Fixed bolus delivered upon button push (e.g., Morphine 1.0 mg, Fentanyl 15-20 mcg, Hydromorphone 0.2 mg).
  • Lockout Interval: Minimum time that must elapse before the pump will deliver another bolus (typically 5 to 8 minutes). The lockout period is calibrated to allow the prior bolus to reach peak central nervous system effect before another dose can be triggered, preventing dose stacking and accidental overdose.
  • Hour Limit: Maximum allowable cumulative dose over a 1- or 4-hour window.
• THE BASAL INFUSION CONTRAINDICATION: The routine prescription of a continuous background (basal) infusion alongside demand doses is STRICTLY CONTRAINDICATED in opioid-naive patients. Basal infusions provide no improvement in pain scores or sleep quality, but dramatically increase the incidence of nocturnal hypoxemia, severe respiratory depression, and fatal cardiac arrest. Specialists may consider basal dosing in selected opioid-tolerant patients, including those on long-term opioids for non-cancer pain, with close respiratory and sedation monitoring.
• PCA by Proxy: The patient is the only person authorized to push the PCA button. Delivery of doses by family members, visitors, or nurses ("PCA by proxy") is a leading cause of fatal hospital overdoses and is strictly forbidden.

Opioid Overdose & The Titrated Naloxone Protocol

• Clinical Diagnostic Triad of Acute Opioid Toxicity:
  1. Pinpoint Pupils (Miosis): Mediated by disinhibition of the Edinger-Westphal nucleus via the parasympathetic oculomotor nerve (CN III). (Note: Severe anoxic brain injury or co-ingestion of meperidine/atropine can cause mydriasis).
  2. Severe Respiratory Depression: Decreased respiratory rate (< 8-10 breaths/min), shallow tidal volumes, Cheyne-Stokes breathing, or frank apnea.
  3. Central Nervous System Depression: Severe somnolence, stupor, or unarousable coma.
• Emergency Resuscitation & Titrated Naloxone Protocol:
  • Airway & Oxygenation First: Administer 100% oxygen via bag-mask ventilation. Restoring oxygenation and ventilation takes absolute precedence over pharmacological reversal.
  • Naloxone (Pure Competitive Opioid Receptor Antagonist): The clinical objective of naloxone administration in postoperative patients is restoration of adequate spontaneous alveolar ventilation (respiratory rate >= 10-12 breaths/min), NOT complete arousal or awakening.
  • Dosing: Dilute a 0.4 mg ampoule in 9 mL of normal saline (giving 0.04 mg/mL). Administer 0.04 to 0.08 mg IV every 2 to 3 minutes, carefully titrating until the patient breathes adequately.
  • The Danger of Large Boluses: Slamming a standard 0.4 to 2.0 mg IV bolus into an opioid-dependent patient precipitates violent acute withdrawal: explosive vomiting, severe excruciating surgical pain, massive sympathetic catecholamine storm, hypertensive crisis, intractable ventricular arrhythmias, and acute non-cardiogenic pulmonary edema.
  • Duration of Action Warning: Naloxone has an elimination half-life of only 30 to 90 minutes, whereas most opioids (morphine, hydromorphone, methadone, modified-release oxycodone) have durations of action ranging from 4 to 24 hours. Respiratory depression can recur as naloxone wears off (renarcotization). Continue monitored care, commonly for at least 6 hours after the last naloxone dose and longer for long-acting/modified-release opioids or persistent toxicity. If repeated boluses are needed to maintain ventilation, start a titrated infusion under senior guidance; a common initial rate is about two-thirds of the effective ventilatory bolus dose per hour.

---

Critical Care Sedation, Weaning & ICU Delirium

Modern intensive care emphasizes minimal sedation, rapid liberation from mechanical ventilation, and early active rehabilitation.

The Richmond Agitation-Sedation Scale (RASS)

The RASS is a validated 10-point clinical scale evaluating depth of sedation and agitation in intensive care:

• Target Sedation Range: The clinical target for mechanically ventilated ICU patients is light sedation: RASS -1 to 0. Deep sedation (RASS -4 to -5) is an independent risk factor for prolonged mechanical ventilation, increased incidence of ICU delirium, ventilator-associated pneumonia, critical illness myopathy, and increased 90-day mortality.

Paired Daily Sedation Vacation: SAT and SBT Protocols

To minimize sedative accumulation and assess readiness for liberation from mechanical ventilation, the ICU team executes daily paired awakening and breathing protocols:

1. Spontaneous Awakening Trial (SAT; Sedation Holiday):
   • First screen for contraindications, including active seizures/withdrawal requiring sedation, neuromuscular blockade, raised intracranial pressure, myocardial ischaemia or severe instability. If eligible, interrupt sedatives under monitoring; continue analgesia needed for active pain.
   • SAT Pass Criteria: Patient awakens and follows simple commands, or tolerates at least 4 hours without the protocol-defined distress/failure criteria.
   • SAT Failure Criteria: Sustained anxiety, agitation (RASS > +2), SpO2 < 88%, tachypnea (> 35 breaths/min), acute hemodynamic instability, or acute cardiac arrhythmias.
2. Spontaneous Breathing Trial (SBT):
   • If the patient passes the SAT and a separate SBT safety screen (adequate oxygenation, spontaneous effort and cardiovascular stability), the ventilator is switched from full support to low-level pressure support (e.g., PSV 5-8 cmH2O, PEEP 5 cmH2O, FiO2 <= 40%) or a T-piece circuit for 30 to 120 minutes.
   • SBT Success: Respiratory rate < 30 breaths/min, hemodynamically stable, no diaphragmatic fatigue, acceptable blood gases. Supports readiness for liberation; also assess cough, secretion clearance and airway protection before extubation.

ICU Delirium & The CAM-ICU Diagnostic Algorithm

Delirium is an acute, fluctuating syndrome characterized by disturbances in attention, awareness, and baseline cognition. It affects up to 60-80% of mechanically ventilated patients and is independently associated with tripling of 6-month mortality and long-term cognitive impairment resembling Alzheimer disease.

• Clinical Delirium Phenotypes:

  • Hyperactive Delirium (10%): Restless, agitated, hallucinating, combative, pulling lines (easily recognized).
  • Hypoactive Delirium (60-70%): Lethargic, quiet, withdrawn, flat affect, reduced motor activity, staring blankly. This is the most common and most lethal phenotype, frequently misdiagnosed as "peaceful sleep" or depression, carrying the highest mortality.
  • Mixed Delirium (20-30%): Fluctuates between hyperactive agitation and hypoactive stupor.

• The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU): First assess arousal: at RASS -4 or -5, record unable to assess and reassess later. At RASS -3 to +4, apply CAM-ICU. Delirium is diagnosed if the patient demonstrates: Feature 1 (Acute Change or Fluctuation) AND Feature 2 (Inattention) AND [Feature 3 (Altered Consciousness) OR Feature 4 (Disorganized Thinking)]

  1. Feature 1: Acute Onset or Fluctuating Course: Is there an acute change from mental status baseline, or has the patient's RASS score fluctuated over the past 24 hours?
  2. Feature 2: Inattention: Assessed via the 10-letter auditory vigilance test: the clinician spells the phrase "S - A - V - E - A - H - A - A - R - T", instructing the patient to squeeze the clinician's hand whenever the letter "A" is spoken. A score of > 2 errors (squeezing on wrong letters or failing to squeeze on letter A) indicates positive inattention.
  3. Feature 3: Altered Level of Consciousness: Any current RASS score other than zero (RASS != 0 within the assessable range -3 to +4).
  4. Feature 4: Disorganized Thinking: Evaluated if RASS is 0 by asking 4 simple logic questions ("Will a stone float on water?", "Are there fish in the sea?", "Does one pound weigh more than two pounds?", "Can you use a hammer to pound a nail?") and one command ("Hold up this many fingers"). More than 1 error indicates disorganized thinking.

Delirium Prevention & The ABCDEF Care Bundle

International ICU guidelines emphasize that non-pharmacological prevention is the primary evidence-based strategy for managing delirium:

• A: Assess, Prevent, and Manage Pain: Treat acute pain before sedating; utilize regional blocks and non-opioids.
• B: Both Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT) daily.
• C: Choice of Sedation: Avoid deliriogenic benzodiazepines (midazolam, lorazepam). Benzodiazepines increase delirium incidence in a dose-dependent fashion. Prefer dexmedetomidine or propofol.
• D: Delirium Assessment, Prevention & Management:
  • Reorientation: clocks, calendars, visible whiteboards with care team names.
  • Sensory optimization: ensure the patient has their hearing aids and eyeglasses.
  • Sleep hygiene: minimize nighttime alarms, avoid nocturnal vitals/blood draws, cluster care, provide earplugs and eye masks, maintain natural daytime light cycles.
• E: Early Mobility and Exercise: Physical therapy out of bed, sitting at edge of bed, ambulation while intubated.
• F: Family Engagement and Empowerment: Presence of familiar family members calms patients and reduces delirium.

Role of Antipsychotics: Routine administration of antipsychotics (haloperidol, quetiapine, olanzapine) does NOT reduce delirium duration, does not shorten ICU stay, and does not decrease mortality. Pharmacological treatment with low-dose haloperidol or quetiapine is reserved strictly for short-term control of severe, distressing hyperactive delirium or hallucinations that threaten patient safety or impede life-saving therapies. Always obtain a baseline 12-lead ECG to rule out QTc prolongation (risk of Torsades de Pointes).